By M. Marin OTCQB: AINMF READ THE FULL AINMF RESEARCH REPORT AINMF believes platform is well-positioned, as use of AI in clinical development is expected to rise NetraMark (OTCQB: AINMF), an AI ...

Kordata, a BIOS Ltd spinout, will advance next-generation clinical trial sites powered with neural recording technologies and ...

China Food and Drug Administration (CFDA) is facing increasing pressure as a backlog of pharmaceutical marketing and clinical trial applications grow, though trial standards there are approaching ...

Medication adherence in clinical trials is hard to verify, but new technologies are fixing that. Discover why traditional ...

Kordata Dynamics exits stealth with a pre-seed funding round from MAVRK Celestia Fund, Kern Venture Group and Digital Neural ...

Despite rapid growth, only 9.2% of DCTs are multiregional and over 80% single-country, indicating challenges in international implementation. 2 With regulatory agencies 4–7 underscoring risk-based ...

During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a ...

Medical device innovation is laborious because of the high bar for validating that the technology does no harm. Patient recruitment for statistically powered trials stretches timelines and drives ...

Faculty in this hub lead the design, coordination, and analysis of clinical trials for cancer treatment, survivorship, vaccine efficacy, infectious disease prevention and treatment, and cancer ...

A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical ...

Kordata Dynamics, a spin-out from Cambridge-based neural engineering business BIOS Health, has emerged from stealth to target ...

Please provide your email address to receive an email when new articles are posted on . JAMA+ Trials is intended to invigorate dialogue about trials and showcase the effort behind them, its editor in ...